In the January 2016 edition of the EJC,
authors from the Gustave Roussy Cancer Centre, Villejuif, France present their rationale for anti-OX40 immunotherapy for
the treatment of cancer. Lead author, Sandrine Aspelaugh, explains why
blocking the OX40 molecule could become an important new approach in
immunotherapy in the EJC’s January podcast. Read
more here.
No comments:
Post a Comment